{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:02:55Z","timestamp":1789016575997,"version":"build-2803163510"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ctrv.2023.102673","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T23:28:35Z","timestamp":1702942115000},"page":"102673","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes"],"prefix":"10.1016","volume":"123","author":[{"given":"Almuth Maria Anni","family":"Merz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"S\u00e9bert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Sonntag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Sophie","family":"Kubasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Ad\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ctrv.2023.102673_b0005","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1182\/blood-2018-10-844696","article-title":"Treatment of MDS","volume":"133","author":"Platzbecker","year":"2019","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.ctrv.2023.102673_b0010","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood-2013-03-492884","article-title":"Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet","volume":"122","author":"Malcovati","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102673_b0015","doi-asserted-by":"crossref","first-page":"106","DOI":"10.6004\/jnccn.2022.0009","article-title":"NCCN guidelines\u00ae insights: myelodysplastic syndromes, version 3.2022","volume":"20","author":"Greenberg","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"10.1016\/j.ctrv.2023.102673_b0020","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evidence"},{"key":"10.1016\/j.ctrv.2023.102673_b0025","doi-asserted-by":"crossref","unstructured":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200\u20131228. doi:10.1182\/blood.2022015850.","DOI":"10.1182\/blood.2022015850"},{"issue":"7","key":"10.1016\/j.ctrv.2023.102673_b0030","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2023.102673_b0035","unstructured":"Research C for DE and. FDA approves ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia. FDA. Published online January 8, 2022. <https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ivosidenib-combination-azacitidine-newly-diagnosed-acute-myeloid-leukemia> [accessed September 8, 2023]."},{"key":"10.1016\/j.ctrv.2023.102673_b0040","unstructured":"Public Health - European Commission. Union Register of medicinal products. <https:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/h1728.htm> [accessed September 8, 2023]."},{"issue":"2","key":"10.1016\/j.ctrv.2023.102673_b0045","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2023.102673_b0050","unstructured":"Research C for DE and. FDA approves luspatercept-aamt for anemia in adults with MDS. FDA. Published online June 4, 2020. <https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-luspatercept-aamt-anemia-adults-mds> [accessed May 20, 2023]."},{"issue":"10399","key":"10.1016\/j.ctrv.2023.102673_b0055","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0140-6736(23)00874-7","article-title":"Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial","volume":"402","author":"Platzbecker","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2023.102673_b0060","unstructured":"IMerge: Results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients (pts) with heavily transfusion dependent (TD) non-del(5q) lower-risk myelodysplastic syndromes (LR-MDS) relapsed\/refractory (R\/R) to erythropoiesis stimulating agents (ESA). | Journal of Clinical Oncology. <https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2023.41.16_suppl.7004> [accessed September 16, 2023]."},{"key":"10.1016\/j.ctrv.2023.102673_b0065","unstructured":"Geron Announces Submission of New Drug Application to FDA for First-in-Class Telomerase Inhibitor Imetelstat. <https:\/\/ir.geron.com\/investors\/press-releases\/press-release-details\/2023\/Geron-Announces-Submission-of-New-Drug-Application-to-FDA-for-First-in-Class-Telomerase-Inhibitor-Imetelstat\/default.aspx> [accessed September 24, 2023]."},{"issue":"6","key":"10.1016\/j.ctrv.2023.102673_b0070","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood.2019004143","article-title":"Oral cedazuridine\/decitabine for MDS and CMML: a phase 2 pharmacokinetic\/pharmacodynamic randomized crossover study","volume":"136","author":"Garcia-Manero","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102673_b0075","doi-asserted-by":"crossref","unstructured":"Kim N, Norsworthy KJ, Subramaniam S, et al. FDA approval summary: decitabine and cedazuridine tablets for myelodysplastic syndromes. Clin Cancer Res. 2022;28(16):3411-3416. doi:10.1158\/1078-0432.CCR-21-4498.","DOI":"10.1158\/1078-0432.CCR-21-4498"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102673_b0080","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3390\/cancers10060158","article-title":"Beyond the edge of hypomethylating agents: novel combination strategies for older adults with advanced MDS and AML","volume":"10","author":"Kubasch","year":"2018","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102673_b0085","first-page":"159","article-title":"Idarubicin in the treatment of acute leukemias. An overview of preclinical and clinical studies","volume":"75","author":"Carella","year":"1990","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.ctrv.2023.102673_b0090","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/1097-0142(20011015)92:8<1999::AID-CNCR1538>3.0.CO;2-B","article-title":"High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens","volume":"92","author":"Beran","year":"2001","journal-title":"Cancer"},{"issue":"23","key":"10.1016\/j.ctrv.2023.102673_b0095","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1182\/blood.V126.23.2884.2884","article-title":"Azacitidine (AZA) combined with idarubicin in higher risk MDS - results of a phase I\/II study by the Groupe Francophone Des Myelodysplasies (GFM)","volume":"126","author":"Sebert","year":"2015","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.ctrv.2023.102673_b0100","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood-2018-99-111756","article-title":"A Randomized Phase II Study of Azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic Acid (VPA) or Idarubicin (IDA) in higher-risk MDS: Gfm\u2019s \u2018pick a Winner\u2019 Trial","volume":"132","author":"Ades","year":"2018","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.ctrv.2023.102673_b0105","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102673_b0110","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa041668","article-title":"Efficacy of lenalidomide in myelodysplastic syndromes","volume":"352","author":"List","year":"2005","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.ctrv.2023.102673_b0115","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1182\/blood-2012-06-434639","article-title":"Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes","volume":"120","author":"Sekeres","year":"2012","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.ctrv.2023.102673_b0120","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.2015.66.2510","article-title":"Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American intergroup study SWOG S1117","volume":"35","author":"Sekeres","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2023.102673_b0125","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102673_b0130","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2007-06-098061","article-title":"Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes","volume":"111","author":"Garcia-Manero","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102673_b0135","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bjh.13016","article-title":"A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome","volume":"167","author":"Kirschbaum","year":"2014","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1016\/j.ctrv.2023.102673_b0140","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1182\/blood.V122.21.386.386","article-title":"A Phase II trial of epigenetic modulators vorinostat in combination with Azacitidine (azaC) in patients with the Myelodysplastic Syndrome (MDS): initial results of study 6898 of the New York cancer consortium","volume":"122","author":"Silverman","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ctrv.2023.102673_b0145","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1038\/leu.2017.159","article-title":"A phase 1b\/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with \u2a7d30% blasts","volume":"31","author":"Garcia-Manero","year":"2017","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102673_b0150","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/cncr.30533","article-title":"Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes","volume":"123","author":"Garcia\u2010Manero","year":"2017","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102673_b0155","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/bjh.13832","article-title":"Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study","volume":"172","author":"Prebet","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2023.102673_b0160","doi-asserted-by":"crossref","unstructured":"Montalban-Bravo G, DiNardo CD, Short N, et al. lsd1. Blood 2022;140(Supplement 1):9771\u20139772. doi:10.1182\/blood-2022-170138.","DOI":"10.1182\/blood-2022-170138"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102673_b0165","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1080\/10428194.2021.2012667","article-title":"Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed\/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes","volume":"63","author":"Roboz","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102673_b0170","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102673_b0175","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/bjh.17689","article-title":"Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome","volume":"195","author":"Chien","year":"2021","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.ctrv.2023.102673_b0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-136855","article-title":"Efficacy and Safety of Sabatolimab (MBG453) in combination with Hypomethylating Agents (HMAs) in patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): updated results from a phase 1b study","volume":"136","author":"Brunner","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102673_b0185","doi-asserted-by":"crossref","unstructured":"Zeidan AM, Ando K, Rauzy O, et al. Primary results of stimulus-MDS1: a randomized, double-blind, placebo-controlled phase II study of TIM-3 inhibition with sabatolimab added to Hypomethylating Agents (HMAs) in adult patients with higher-risk Myelodysplastic Syndromes (MDS). Blood 2022;140(Supplement 1):2063\u20132065. doi:10.1182\/blood-2022-158612.","DOI":"10.1182\/blood-2022-158612"},{"issue":"22","key":"10.1016\/j.ctrv.2023.102673_b0190","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood.V128.22.344.344","article-title":"A phase II study evaluating the combination of Nivolumab (Nivo) or Ipilimumab (Ipi) with Azacitidine in Pts with Previously Treated or Untreated Myelodysplastic Syndromes (MDS)","volume":"128","author":"Garcia-Manero","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102673_b0195","doi-asserted-by":"crossref","unstructured":"Zeidan AM, Knaus HA, Robinson TM, et al. A multi-center phase I trial of ipilimumab in patients with myelodysplastic syndromes following hypomethylating agent failure. Clin Cancer Res 2018;24(15):3519\u20133527. doi:10.1158\/1078-0432.CCR-17-3763.","DOI":"10.1158\/1078-0432.CCR-17-3763"},{"key":"10.1016\/j.ctrv.2023.102673_b0200","doi-asserted-by":"crossref","unstructured":"Garcia JS, Flamand Y, Penter L, et al. Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-na\u00efve settings. Blood 2023;141(15):1884\u20131888. doi:10.1182\/blood.2022017686.","DOI":"10.1182\/blood.2022017686"},{"issue":"Supplement 1","key":"10.1016\/j.ctrv.2023.102673_b0205","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1182\/blood-2018-99-118948","article-title":"Double immune checkpoint inhibitor blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS)","volume":"132","author":"Garcia-Manero","year":"2018","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ctrv.2023.102673_b0210","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1182\/bloodadvances.2021006138","article-title":"A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML","volume":"6","author":"Zeidan","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102673_b0215","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1182\/bloodadvances.2021005240","article-title":"Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome","volume":"6","author":"Gerds","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.ctrv.2023.102673_b0220","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1038\/s41375-021-01125-4","article-title":"Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS\/CMML or low-blast AML","volume":"35","author":"Sekeres","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2023.102673_b0225","doi-asserted-by":"crossref","unstructured":"Ad\u00e8s L, Girshova L, Doronin VA, et al. Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS\/chronic myelomonocytic leukemia or low-blast-percentage AML. Blood Adv 2022;6(17):5132\u20135145. doi:10.1182\/bloodadvances.2022007334.","DOI":"10.1182\/bloodadvances.2022007334"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102673_b0230","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ctrv.2023.102673_b0235","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","article-title":"Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure","volume":"29","author":"Pr\u00e9bet","year":"2011","journal-title":"JCO"},{"issue":"21","key":"10.1016\/j.ctrv.2023.102673_b0240","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.ctrv.2023.102673_b0245","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and Azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.ctrv.2023.102673_b0250","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the Groupe Francophone des My\u00e9lodysplasies (GFM)","volume":"39","author":"Cluzeau","year":"2021","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2023.102673_b0255","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.1200\/JCO.2022.40.16_suppl.7017","article-title":"Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 phase 1b study results","volume":"40","author":"Sallman","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2023.102673_b0260","unstructured":"Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS. <https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2023\/7\/gilead-to-discontinue-phase-3-enhance-study-of-magrolimab-plus-azacitidine-in-higher-risk-mds> [accessed August 31, 2023]."},{"key":"10.1016\/j.ctrv.2023.102673_b0265","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.leukres.2017.11.006","article-title":"A phase 1\/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia","volume":"64","author":"Navada","year":"2018","journal-title":"Leuk Res"},{"key":"10.1016\/j.ctrv.2023.102673_b0270","doi-asserted-by":"crossref","first-page":"106369","DOI":"10.1016\/j.leukres.2020.106369","article-title":"Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study","volume":"94","author":"Navada","year":"2020","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102673_b0275","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1470-2045(16)00009-7","article-title":"Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial","volume":"17","author":"Garcia-Manero","year":"2016","journal-title":"Lancet Oncol"},{"issue":"29","key":"10.1016\/j.ctrv.2023.102673_b0280","doi-asserted-by":"crossref","first-page":"47103","DOI":"10.18632\/oncotarget.17482","article-title":"BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia","volume":"8","author":"Vidal","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102673_b0285","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/ajh.26771","article-title":"A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes","volume":"98","author":"Zeidan","year":"2023","journal-title":"Am J Hematol"},{"issue":"Supplement_1","key":"10.1016\/j.ctrv.2023.102673_b0290","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1182\/blood-2019-124437","article-title":"A Phase 1b study evaluating the safety and efficacy of venetoclax in combination with azacitidine in treatment-na\u00efve patients with higher-risk myelodysplastic syndrome","volume":"134","author":"Wei","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102673_b0295","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/leu.2015.211","article-title":"IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression","volume":"30","author":"DiNardo","year":"2016","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102673_b0300","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.ctrv.2023.102673_b0305","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with Ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2023.102673_b0310","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Venugopal S, Lachowiez C, et al. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. Blood Adv 2023;7(11):2378\u20132387. doi:10.1182\/bloodadvances.2022008378.","DOI":"10.1182\/bloodadvances.2022008378"},{"key":"10.1016\/j.ctrv.2023.102673_b0315","doi-asserted-by":"crossref","unstructured":"Stubbins RJ, Platzbecker U, Karsan A. Inflammation and myeloid malignancy: quenching the flame. Blood. 2022;140(10):1067\u20131074. doi:10.1182\/blood.2021015162.","DOI":"10.1182\/blood.2021015162"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2023.102673_b0320","doi-asserted-by":"crossref","first-page":"7016","DOI":"10.1200\/JCO.2022.40.16_suppl.7016","article-title":"Phase 1\/2a study of the IRAK4 inhibitor CA-4948 as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed\/refractory (R\/R) acute myeloid leukemia or lyelodysplastic syndrome","volume":"40","author":"Garcia-Manero","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2023.102673_b0325","doi-asserted-by":"crossref","first-page":"106713","DOI":"10.1016\/j.leukres.2021.106713","article-title":"Combination of dociparstat sodium (DSTAT), a CXCL12\/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS","volume":"110","author":"Huselton","year":"2021","journal-title":"Leuk Res"},{"key":"10.1016\/j.ctrv.2023.102673_b0330","doi-asserted-by":"crossref","unstructured":"de Botton S, Cluzeau T, Vigil C, et al. Targeting RARA overexpression with tamibarotene, a potent and selective RAR\u03b1 agonist, is a novel approach in AML. Blood Adv 2022;7(9):1858-1870. doi:10.1182\/bloodadvances.2022008806.","DOI":"10.1182\/bloodadvances.2022008806"},{"key":"10.1016\/j.ctrv.2023.102673_b0335","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/978-3-642-01222-8_16","article-title":"Imetelstat (GRN163L)\u2013telomerase-based cancer therapy","volume":"184","author":"R\u00f6th","year":"2010","journal-title":"Recent Results Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102673_b0340","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3343\/alm.2017.37.3.195","article-title":"Dysregulation of telomere lengths and telomerase activity in myelodysplastic syndrome","volume":"37","author":"Park","year":"2017","journal-title":"Ann Lab Med"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102673_b0345","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/gcc.20737","article-title":"Telomere shortening and chromosomal instability in myelodysplastic syndromes","volume":"49","author":"Lange","year":"2010","journal-title":"Genes Chromosom Cancer"},{"issue":"10","key":"10.1016\/j.ctrv.2023.102673_b0350","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.leukres.2005.03.006","article-title":"Telomerase activity in myelodysplastic syndromes","volume":"29","author":"G\u00fcrkan","year":"2005","journal-title":"Leuk Res"},{"issue":"10","key":"10.1016\/j.ctrv.2023.102673_b0355","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1056\/NEJMoa1503479","article-title":"Telomerase inhibitor Imetelstat in patients with essential thrombocythemia","volume":"373","author":"Baerlocher","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ctrv.2023.102673_b0360","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa1310523","article-title":"A pilot study of the telomerase inhibitor imetelstat for myelofibrosis","volume":"373","author":"Tefferi","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102673_b0365","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/leu.2012.178","article-title":"Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin","volume":"27","author":"Kurimoto","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102673_b0370","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/leu.2015.244","article-title":"A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"30","author":"Daver","year":"2016","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.ctrv.2023.102673_b0375","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102673_b0380","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ajh.24972","article-title":"A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome\/myeloproliferative neoplasms","volume":"93","author":"Assi","year":"2018","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.ctrv.2023.102673_b0385","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.3324\/haematol.2015.127985","article-title":"Karyotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia","volume":"100","author":"Meggendorfer","year":"2015","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.ctrv.2023.102673_b0390","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1470-2045(18)30240-7","article-title":"Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial","volume":"19","author":"Cortes","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102673_b0395","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102673_b0400","doi-asserted-by":"crossref","first-page":"34","DOI":"10.18632\/oncotarget.106","article-title":"Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome","volume":"1","author":"Raffoux","year":"2010","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102673_b0405","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-023-01476-8","article-title":"A phase 1\/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents","volume":"16","author":"Short","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"20","key":"10.1016\/j.ctrv.2023.102673_b0410","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102673_b0415","first-page":"358","article-title":"Prognostic factors and scoring systems in myelodysplastic syndromes","volume":"83","author":"Sanz","year":"1998","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2023.102673_b0420","doi-asserted-by":"crossref","unstructured":"Santini V, Platzbecker U, Fenaux P, et al. Disease Characteristics and International Prognostic Scoring Systems (IPSS, IPSS-R, IPSS-M) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Participating in Two Randomized, Double-Blind, Placebo-Controlled Studies with Intravenous Sabatolimab Added to Hypomethylating Agents (HMA) (STIMULUS-MDS1 and MDS2). Blood. 2022;140(Supplement 1):1340-1342. doi:10.1182\/blood-2022-160282.","DOI":"10.1182\/blood-2022-160282"},{"key":"10.1016\/j.ctrv.2023.102673_b0425","unstructured":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms - PubMed. Accessed September 20, 2023. https:\/\/pubmed.ncbi.nlm.nih.gov\/35732831\/."},{"issue":"10","key":"10.1016\/j.ctrv.2023.102673_b0430","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1038\/s41375-023-02004-w","article-title":"Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS\/AML overlap patients defined by ICC","volume":"37","author":"Huber","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2023.102673_b0435","doi-asserted-by":"crossref","first-page":"101128","DOI":"10.1016\/j.blre.2023.101128","article-title":"Classification, risk stratification and response assessment in myelodysplastic syndromes\/neoplasms (MDS): a state-of-the-art report on behalf of the International Consortium for MDS (icMDS)","volume":"62","author":"Stahl","year":"2023","journal-title":"Blood Rev"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102673_b0440","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/s41375-023-01831-1","article-title":"Risk prediction in MDS: independent validation of the IPSS-M\u2014ready for routine?","volume":"37","author":"Baer","year":"2023","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.ctrv.2023.102673_b0445","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.clml.2016.08.005","article-title":"Changes in the updated 2016: WHO classification of the myelodysplastic syndromes and related myeloid neoplasms","volume":"16","author":"Bennett","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1016\/j.ctrv.2023.102673_b0450","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1182\/blood-2015-01-624239","article-title":"Revisiting the case for genetically engineered mouse models in human myelodysplastic syndrome research","volume":"126","author":"Zhou","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102673_b0455","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2017-01-763219","article-title":"Robust patient-derived xenografts of MDS\/MPN overlap syndromes capture the unique characteristics of CMML and JMML","volume":"130","author":"Yoshimi","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102673_b0460","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3324\/haematol.2017.183202","article-title":"Cytokines increase engraftment of human acute myeloid leukemia cells in immunocompromised mice but not engraftment of human myelodysplastic syndrome cells","volume":"103","author":"Krevvata","year":"2018","journal-title":"Haematologica"},{"issue":"19","key":"10.1016\/j.ctrv.2023.102673_b0465","doi-asserted-by":"crossref","first-page":"14993","DOI":"10.18632\/oncotarget.24538","article-title":"Molecular dissection of engraftment in a xenograft model of myelodysplastic syndromes","volume":"9","author":"Meunier","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102673_b0470","article-title":"A highly efficient and faithful MDS patient-derived xenotransplantation model for pre-clinical studies","volume":"10","author":"Song","year":"2019","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102673_b0475","doi-asserted-by":"crossref","first-page":"864","DOI":"10.3324\/haematol.2019.233320","article-title":"Myelodysplastic syndrome patient-derived xenografts: from no options to many","volume":"105","author":"C\u00f4me","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2023.102673_b0480","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). Published online 2017."},{"issue":"3","key":"10.1016\/j.ctrv.2023.102673_b0485","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/bjh.18193","article-title":"A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM\u2019s \u201cpick a winner\u201d trial, with the impact of somatic mutations","volume":"198","author":"Ad\u00e8s","year":"2022","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102673_b0490","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s11899-021-00627-3","article-title":"Evolution of hematology clinical trial adverse event reporting to improve care delivery","volume":"16","author":"Miller","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.ctrv.2023.102673_b0495","unstructured":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel | Blood | American Society of Hematology. <https:\/\/ashpublications.org\/blood\/article\/129\/4\/424\/36196\/Diagnosis-and-management-of-AML-in-adults-2017-ELN> [accessed September 23, 2023]."},{"issue":"2","key":"10.1016\/j.ctrv.2023.102673_b0500","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.ctrv.2023.102673_b0505","first-page":"2047","article-title":"Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes","volume":"141","author":"Zeidan","year":"2023","journal-title":"Blood"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737223001664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737223001664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:30:35Z","timestamp":1759656635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737223001664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":101,"alternative-id":["S0305737223001664"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2023.102673","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2023.102673","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102673"}}